/   Home   /   Newsroom   /   Research News

Old Drug, New Trick: Repurposing Axitinib for Gastrointestinal Stromal Tumors

Jul 12, 2019     Email"> PrintText Size

The research group led by Prof. LIU Qingsong and Prof. LIU Jing at High Magnetic Field Laboratory, Chinese Academy of Sciences (CHMFL) recently discovered that Axitinib, a clinically approved drug for renal cell carcinoma (RCC), exhibited the potential against gastrointestinal stromal tumors.

cKIT kinase over expression and gain-of-function mutations are the critical pathogenesis of GISTs, which are the most common mesenchymal tumors of the gastrointestinal tract.

Although Imatinib as the first line treatment has remarkably improved the GISTs patients' survival, varieties of mutations including those occur in the ATP binding pocket of cKIT kinase like T670I, V654A and activation loop such as D816V/H, N822K etc. are resistant to Imatinib.

Second line treatment such as Sunitinib and Regorafenib could overcome some of those mutations. However, their poor clinical response rate and the toxicity associated with the off-targets leave a great demand of new target therapies for GISTs with different mutant sensitivity spectrum.

Via a high throughput screening approach of the known clinically used drugs, the researchers at CHMFL discovered that Axitinib exhibited potent activities against Imatinib-resistant mutations in the ATP binding pocket including T670I and V654A.

In addition, it also displayed better activities than Imatinib against primary mutations occurred in the juxtamembrane domain including L576P, V559D and secondary mutations occurred in the activation loop including D816V/H, N822K and A829P.

These effects were also confirmed in the in vivo preclinical GISTs models and primary GIST patient-derived cell model.

Given the fact that Axitinib has been widely used in the clinic and its human PK/ADMET properties have been well characterized, its different cKIT mutant sensitivity spectrum would make it a valuable potential drug candidate for those drug resistant/intolerant GISTs patients.

This work was supported by the National Natural Science Foundation of China and the "Personalized Medicines Molecular Signature-Based Drug Discovery and Development", Strategic Priority Research Program of the Chinese Academy of Sciences.


Drug repurposing strategy for Axitinib against GISTs (Image by LIU Feiyang)

(Editor: ZHANG Nannan)

Related Articles

drug;drug repurposing;aabozantinib;GISTs

Drug Repurposing May Help to Fight Gastrointestinal Stromal Tumors, New Study Says

Mar 06, 2019

Drug repurposing is an efficient approach that explores new available therapies for the unmet clinical demands. Cabozantinib, described in this work, is a multi-target kinase inhibitor already approved for treating advanced renal cell carcinoma (RCC) a...

drug;systemic lupus erythematosus;clincal trial

Watchdog Approves Clinical Trial for SLE Drug

May 21, 2015

China's food and drug watchdog approved clinical trial for a drug for the treatment of systemic lupus erythematosus (SLE), giving new hope to patients in China. "The spread of SLE is 10 times higher among Asians than the Westerners. Therefore, developi...


Chinese Scientists Develop Nanogenerator for Cancer Drug Delivery System

Feb 22, 2019

Scientists from the Beijing Institute of Nanoenergy and Nanosystems under the Chinese Academy of Sciences (CAS) as well as the Institute of Process Engineering under the CAS have developed a triboelectric nanogenerator that can act as an electricity su...

Contact Us

Copyright © 2002 - Chinese Academy of Sciences